Globus Medical, Inc.
HealthcareNYSE:GMED · New York Stock Exchange
-$0.13 today
Vol 1.21M · Avg 1.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.8%
avg 9.7%
ROIC
8.8%
avg 8.7%
ROA
10.1%
avg 8.6%
Analysis
ROE is currently the strongest return metric at 11.8% versus its period average of 9.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David C. Paul | Co-Founder & Executive Chairman | $1.62M | — | 59 | $510,175.00 | 0.38% |
Keith W. Pfeil | Chief Executive Officer, President & Director | $1.42M | — | 47 | $100,000.00 | 0.07% |
Kelly G. Huller | Executive Vice President, General Counsel & Corporate Secretary | $850,362.00 | — | 54 | $20,000.00 | 0.01% |
Kyle R. Klin | Senior Vice President & Chief Financial Officer | $617,304.00 | — | 40 | $30,000.00 | 0.02% |
Brian J. Kearns | Senior Vice President of Business Development & Investor Relations | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$13.71M
Net Sentiment
$13.71M
Net selling
Most Active
Huller Kelly
3 transactions
1–10 of 13
Analysis
Insiders reported 0 buys worth $0.00 and 13 sells worth $13.71M over the last 12 months. That adds up to net selling of $13.71M. Huller Kelly was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +13.5% | +12.4% (15yr)2 analysts |
| Revenue | N/A | N/A | +12.2% | +14.5% (15yr)4 analysts |
| Net Income | N/A | N/A | +15.2% | +15.1% (15yr)4 analysts |
| EBIT | N/A | N/A | +14.5% | +9.9% (15yr)4 analysts |
Analysis
Recent growth has been strongest in Net Income at +15.2% over three years. Forward estimates point to Net Income at +15.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Penumbra, Inc.
NYSE:PEN
$12.54B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
HealthEquity, Inc.
NASDAQ:HQY
$7.39B
Grifols, S.A.
NASDAQ:GRFS
$6.46B
Who manages GMED?
Globus Medical, Inc. (GMED) lists 5 active executives. The top listed executive is Keith W. Pfeil, Chief Executive Officer, President & Director.
Are GMED insiders buying or selling?
Recent insider activity shows net buying of $84.67M.
Explore More
Continue the stock analysis
Jump to another research area for this company.